ArticleBone marrow transplantation2018

Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy.

C Amos Clark et al.PubMed ↗Publisher ↗

No numbers read from the abstract.